Continuing Advanced Therapy May Reduce Crohn's Surgery Risks

American College of Surgeons

CHICAGO – Patients with Crohn's disease who continue advanced therapies, including biologics and small-molecule drugs, in the months before elective colorectal surgery may have a lower risk of two postoperative complications: anastomotic leak and organ space surgical site infection, according to a study published in the Journal of the American College of Surgeons .

These findings challenge previous thoughts that immunosuppressive therapies should be stopped before surgery due to concerns about postoperative complications . In contrast, advanced therapy use was associated with improved outcomes and lower risk of anastomotic leak and organ space surgical site infection , a feared complication of colorectal surgery.

The retrospective analysis from 2021 to 2024 includes 1,150 patients at 24 centers in the American College of Surgeons NSQIP-Inflammatory Bowel Disease Collaborative . After adjusting baseline differences, anastomotic leak or organ space surgical site infection occurred in 2.43% of patients who received advanced therapy compared with 6.46% of those who did not. There was no statistically significant difference in superficial surgical site infection, deep incisional surgical site infection, or wound dehiscence.

Crohn's disease is a chronic inflammatory condition of the digestive tract that often requires surgical removal of diseased areas of the lower digestive system and reconnection of the remaining intestine, called an anastomosis . An anastomotic leak, in which a hole forms at the reconnection and poop leaks into the abdomen, is a potentially devastating complication that can require emergency reoperation or prolonged hospitalization.

Historically, the immunosuppressive nature of advanced therapies raised concerns that they might impair wound healing, similar to the well-established effects of corticosteroids.

"The previous school of thought was if a patient needs surgery, you need to stop advanced therapies beforehand, because there was concern that they would be associated with worse outcomes including weakened wound healing or anastomotic leaks," said lead author Nicholas C. Neel, MD, a surgery resident and researcher at the University of California San Diego. "The first studies that came out seemed to support that, but as we've gotten more data, that signal isn't as strong as we thought and these data seem to suggest the opposite is true."

The study focused specifically on elective surgeries, in which patients can be optimized in advance. In urgent or emergent cases, surgery proceeds regardless of medication status. The researchers also examined Crohn's disease separately from ulcerative colitis and found the signal was concentrated in Crohn's patients. Anti-TNF agents were the most common therapy (46%), followed by anti-IL-23 (33%) and anti-integrin agents (12%).

"It was interesting that no matter how we sliced the data, there seemed to be a signal associated with the use of advanced therapies and some better outcomes," Neel said.

The authors emphasize that the findings are associative and likely reflect better disease control through reduced systemic inflammation and improved mucosal healing rather than a direct pharmacologic effect of the drugs. They call for confirmation in larger datasets with sufficient power for drug-class-specific adjusted analyses.

Study co-authors include Nicole Raclin, MD; Dong-Jin "Eastern" Kang Sim, PhD; Nicole Lopez, MD, FACS; Lisa Parry, MD, FACS; Benjamin Abbadessa, MD, FACS; Shanglei Liu, MD; Bard Cosman, MD, FACS; Sonia Ramamoorthy, MD, FACS; Stefan D. Holubar, MD, FACS; and Samuel Eisenstein, MD, FACS, on behalf of the NSQIP-IBD Collaborative.

The study was supported by the NIH National Library of Medicine, the American Society of Colon and Rectal Surgery General Surgery Research Initiation Grant, and research funding from the Crohn's and Colitis Foundation. Dr. Eisenstein is a paid consultant for ECM Therapeutics.

Citation: Neel NC, Raclin N, Kang Sim DJ, et al. Preoperative Advanced Therapy Use and Anastomotic Complications After Elective Surgery for Crohn's Disease. Journal of the American College of Surgeons. 2026.

About the American College of Surgeons

The American College of Surgeons (ACS) is a scientific and educational organization of surgeons founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The ACS is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and established it as an important advocate for all surgical patients. The ACS has more than 95,000 members and is the largest organization of surgeons in the world. "FACS" designates that a surgeon is a Fellow of the ACS.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.